<SEC-DOCUMENT>0001493152-26-016176.txt : 20260410
<SEC-HEADER>0001493152-26-016176.hdr.sgml : 20260410
<ACCEPTANCE-DATETIME>20260410163041
ACCESSION NUMBER:		0001493152-26-016176
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260410
DATE AS OF CHANGE:		20260410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AIM ImmunoTech Inc.
		CENTRAL INDEX KEY:			0000946644
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				520845822
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286319
		FILM NUMBER:		26855292

	BUSINESS ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801
		BUSINESS PHONE:		352-448-7797

	MAIL ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEMISPHERX BIOPHARMA INC
		DATE OF NAME CHANGE:	19950614
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(5)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-286319</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
NO. 1 DATED APRIL 10, 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
Prospectus Supplement dated October 30, 2025 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
Prospectus Dated July 3, 2025)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to $3,409,174</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AIM
IMMUNOTECH INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our
prospectus supplement dated October 30, 2025, which together with the accompanying prospectus dated July 3, 2025 contained in our Registration
Statement on Form S-3 (Registration No. 333-286319), we refer to as the prospectus, relating to the offering, issuance and sale of shares
of our common stock, par value $0.001 per share, from time to time through our sales agent, Maxim Group LLC, or Maxim. These sales, if
any, will be made pursuant to the terms of the Equity Distribution Agreement, as amended, or the EDA, we entered into with Maxim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement should be read in conjunction with, is not complete without, and may not be delivered or utilized except in connection
with, the prospectus, including all supplements thereto and documents incorporated by reference therein. If there is any inconsistency
between the information in the prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
Any information that is modified or superseded in the prospectus shall not be deemed to constitute a part of the prospectus, except as
modified or superseded by this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 10, 2026, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately
$10,227,521, which was calculated based on 8,182,017 shares of our outstanding common stock held by non-affiliates at a
price of $1.25 per share, the closing price of our common stock on February 13, 2026. Pursuant to General Instruction I.B.6 of Form S-3,
in no event will we sell shares pursuant to this prospectus supplement with a value of more than one-third of the aggregate market value
of our common stock held by non-affiliates in any 12-month period, or $3,409,174. As of the date of this prospectus supplement,
we have sold approximately $2,288,758.60 of securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months
prior to, and including, the date of this prospectus supplement, and are therefore eligible to sell up to an additional $1,120,415
of our securities pursuant to General Instruction I.B.6 of Form S-3. Pursuant to General Instruction I.B.6 of Form S-3, in no event will
we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third
of the aggregate market value of our voting and non-voting common equity held by non-affiliates in any 12-month period so long as our
public float remains below $75 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are filing this prospectus supplement to supplement and amend, as of April 10, 2026, the prospectus, as supplemented, to increase the
maximum aggregate offering price of our common stock that may be offered, issued and sold under the prospectus, as supplemented and amended
by this prospectus supplement, pursuant to the EDA with Maxim to up to approximately $3,409,174.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on the NYSE American under the symbol &ldquo;AIM.&rdquo; On April 9, 2026, the last reported sale price of our
common stock was $0.5180 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our common stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed to be &ldquo;at
the market offerings&rdquo; as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act. Maxim is not
required to sell any specific number or dollar amount of securities but will act as a sales agent using commercially reasonable efforts
consistent with its normal trading and sales practices, on terms mutually agreed to by Maxim and us. There is no arrangement for funds
to be received in any escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation to Maxim for sales of common stock sold pursuant to the EDA will be up to 3.0% of the gross proceeds of any shares of common
stock sold under the EDA. In connection with the sale of the common stock on our behalf, Maxim will be deemed to be an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act and the compensation of Maxim will be deemed to be underwriting commissions or discounts. We
have also agreed to provide indemnification and contribution to Maxim with respect to certain liabilities, including liabilities under
the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk. See &ldquo;<I>Risk Factors</I>&rdquo; beginning on page S-7 of the prospectus supplement
dated October 30, 2025, page 3 of the accompanying prospectus and under similar headings in the documents incorporated by reference into
this prospectus supplement and the accompanying prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal
offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maxim
Group LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus supplement is April 10, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T &(# 2(  A$! Q$!_\0
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DI! 'OGO111[6?<+(Z>WMH[:VB@CW!(T"*"QZ 8%%%%<YJ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
